시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 C-X-C 케모카인 수용체 4(CXCR4) 길항제 시장 보고서(2025년)
C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Global Market Report 2025
상품코드 : 1704072
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 200 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,203,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 8,967,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,730,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

C-X-C 케모카인 수용체 4(CXCR4) 길항제 시장 규모는 향후 수년간 강력한 성장세를 보이며 2029년까지 연평균 9.3%의 성장률로 25억 4,000만 달러에 달할 것으로 예상됩니다. 예측 기간 중의 성장은 HIV 및 AIDS에서의 용도 확대, 줄기세포 동원에 대한 수요 증가, 자가면역질환에서의 잠재력, 바이오뱅크 개념의 성장, 신약개발에 인공지능(AI)의 통합 등에 기인할 것으로 보입니다. 예측 기간 중 주요 동향으로는 희귀질환 치료제 개발에 대한 관심 증가, 병용요법 개발, 정밀 종양학 접근법 채택, 신규 치료제 임상시험 확대, 약물전달 기술 발전 등을 꼽을 수 있습니다.

HIV는 CD4(T) 세포를 공격하여 면역 체계를 표적으로 삼고 약화시키는 바이러스로, 치료하지 않으면 AIDS로 이어질 수 있으며, HIV 유병률이 증가함에 따라 경련성 발성 장애 치료 시장의 성장을 가속할 것으로 예상됩니다. CXCR4 길항제는 CXCR4 수용체를 억제하여 바이러스가 면역세포에 접근하여 감염되는 것을 막음으로써 HIV를 억제하고, HIV가 면역세포에 접근하여 감염되는 것을 방지합니다. 방지합니다. 예를 들어 유엔에이즈계획(UNAIDS)에 따르면 2022년에는 전 세계 3,900만 명(3,310만-4,570만 명)의 HIV 감염자가 있으며, 그 해 신규 감염자는 130만 명(100만-170만 명)에 달할 것으로 예상됩니다. 결과적으로 HIV 유병률 증가는 CXCR4 길항제 시장 확대에 박차를 가하고 있습니다.

CXCR4 길항제 시장의 주요 기업은 다양한 질환의 치료 옵션과 환자 예후를 개선하기 위해 생물학적 동등물 개발에 주력하고 있습니다. 생물학적 동등물이란 유사한 조건에서 비교했을 때 유사한 생체 이용률을 가진 의약품을 말합니다. 예를 들어 2024년 5월 인도의 제네릭 주사제 제조업체인 글랜드 파마(Gland Pharma)는 미국 식품의약국(FDA)으로부터 프레릭사포(Prelixafor) 주사제를 승인받았습니다. 이 제품은 젠자임 코퍼레이션의 오리지널 의약품인 MOZOBIL(프레릭사포르) 주사제와 생물학적으로 동등하며, 치료적 측면에서도 동등합니다. 프레릭사홀은 CXCR4 길항제로 비호지킨림프종 및 다발성골수종 환자에서 조혈모세포를 말초혈액으로 동원하여 채취 및 자가이식을 위해 과립구 콜로니 자극인자와 병용투여합니다.

목차

제1장 개요

제2장 시장의 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 신형 코로나바이러스 및 경기회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별·국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 개요

제31장 기타 대기업과 혁신적 기업

제32장 세계의 시장 경쟁 벤치마킹과 대시보드

제33장 주요 합병과 인수

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KSA
영문 목차

영문목차

C-X-C chemokine receptor 4 (CXCR4) antagonists are pharmaceutical compounds aimed at inhibiting the CXCR4 receptor, which is found on the surface of specific cells. These antagonists function by blocking the interaction between CXCR4 and its ligand, CXCL12 (also known as SDF-1), a key player in cell migration, hematopoiesis, and immune responses.

The main types of CXCR4 antagonists include BL-8040, GMI-1359, plerixafor (AMD3100), balixafortide (POL6326), USL311, burixafor (GPC-100), and others. These antagonists can be administered orally or via injection. BL-8040, for example, is a synthetic peptide developed to block CXCR4, which is involved in cancer cell migration and survival. The product pipelines feature both approved clinical trials and pre-clinical trials for a range of applications, including cancer, human immunodeficiency virus (HIV), chronic inflammatory diseases, stem cell mobilization, and immune and autoimmune diseases. These products are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

The C-X-C chemokine receptor 4 (CXCR4) antagonist market research report is one of a series of new reports from The Business Research Company that provides C-X-C chemokine receptor 4 (CXCR4) antagonist market statistics, including C-X-C chemokine receptor 4 (CXCR4) antagonist industry global market size, regional shares, competitors with a C-X-C chemokine receptor 4 (CXCR4) antagonist market share, detailed C-X-C chemokine receptor 4 (CXCR4) antagonist market segments, market trends and opportunities, and any further data you may need to thrive in the C-X-C chemokine receptor 4 (CXCR4) antagonist industry. This C-X-C chemokine receptor 4 (CXCR4) antagonist market research report delivers a complete perspective on everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The C-X-C chemokine receptor 4 (CXCR4) antagonists market size has grown strongly in recent years. It will grow from $1.62 billion in 2024 to $1.78 billion in 2025 at a compound annual growth rate (CAGR) of 9.7%. The growth in the historic period can be attributed to increasing transparency in clinical trial data, patient-centric healthcare policies, rising prevalence of chemotherapy resistance, policies emphasizing patient-centered care and access, and increasing preference for targeted therapies.

The C-X-C chemokine receptor 4 (CXCR4) antagonists market size is expected to see strong growth in the next few years. It will grow to $2.54 billion in 2029 at a compound annual growth rate (CAGR) of 9.3%. The growth in the forecast period can be attributed to expanding applications in HIV or AIDS, rising demand for stem cell mobilization, potential in autoimmune diseases, growth in biobanking initiatives, and integration of artificial intelligence (AI) in drug discovery. Major trends in the forecast period include increasing focus on orphan drug development, development of combination therapies, adoption of precision oncology approaches, expanding clinical trials for novel therapies, and advancements in drug delivery technologies.

The rise in human immunodeficiency virus (HIV) prevalence is expected to drive growth in the spasmodic dysphonia treatment market. HIV, a virus that targets and weakens the immune system by attacking CD4 (T) cells, can lead to AIDS if untreated. The increasing prevalence of HIV is due to factors such as low awareness, limited healthcare access, high transmission rates, and inadequate prevention in some regions. CXCR4 antagonists help manage HIV by blocking the CXCR4 receptor, preventing the virus from accessing and infecting immune cells, thus aiding in controlling the virus and enhancing immune response. For instance, according to Joint United Nations Programme on HIV/AIDS (UNAIDS), in 2022, there were 39 million [33.1 million-45.7 million] people living with HIV globally, with 1.3 million [1 million-1.7 million] new infections that year. Consequently, the growing prevalence of HIV is fueling the expansion of the CXCR4 antagonist market.

Leading companies in the CXCR4 antagonist market are focusing on developing bioequivalents to improve treatment options and patient outcomes for various diseases. Bioequivalents are pharmaceutical products that have similar bioavailability when compared under similar conditions. For example, in May 2024, Gland Pharma, an India-based generic injectable manufacturer, received approval from the United States Food and Drug Administration (US FDA) for Plerixafor Injection. This product is bioequivalent and therapeutically equivalent to the reference drug, MOZOBIL (plerixafor) injection by Genzyme Corporation. Plerixafor is a CXCR4 antagonist used in conjunction with granulocyte-colony stimulating factor to mobilize hematopoietic stem cells into the peripheral blood for collection and autologous transplantation in patients with non-Hodgkin's lymphoma and multiple myeloma.

In April 2024, PANTHERx, a US-based specialty pharmacy, partnered with X4 Pharmaceuticals Inc. to facilitate the distribution of XOLREMDI (mavorixafor). This oral treatment, taken once daily, selectively antagonizes the CXCR4 receptor and was approved by the U.S. Food and Drug Administration (FDA). It is the first FDA-approved therapy specifically indicated for patients aged 12 and older with warts, hypogammaglobulinemia, infections, and myelokathexis (WHIM) syndrome. X4 Pharmaceuticals Inc., a US-based late-stage clinical biopharmaceutical company, focuses on developing and commercializing novel therapeutics, including CXCR4 antagonists such as XOLREMDI (mavorixafor).

Major companies operating in the C-X-C chemokine receptor 4 (CXCR4) antagonists market are Pfizer Inc., F-Hoffmann La Roche Ltd., Sanofi, Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline, Eli Lilly and Company, Amgen Inc., Takeda Chemical Industries Ltd., Kyowa Kirin Co. Ltd., BioLegend Inc., Kura Oncology Inc., CUSABIO TECHNOLOGY LLC, Cayman Chemical, X4 Pharmaceuticals Inc., BioLineRx Ltd., Spexis Ltd., Biokine Therapeutics Ltd., GlycoMimetics, AnorMED Inc., CohBar Inc.

North America was the largest region in the C-X-C chemokine receptor type 4 antagonists market in 2024. The regions covered in the C-X-C chemokine receptor 4 (CXCR4) antagonists market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the C-X-C chemokine receptor 4 (CXCR4) antagonists market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The C-X-C chemokine receptor 4 (CXCR4) antagonist market consists of sales of TN14003 (Trogarzo), X4P-001 (Mavorixafor), TG-0054, and KRH-3955. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on c-x-c chemokine receptor 4 (cxcr4) antagonists market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for c-x-c chemokine receptor 4 (cxcr4) antagonists ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The c-x-c chemokine receptor 4 (cxcr4) antagonists market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Characteristics

3. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Trends And Strategies

4. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Growth Analysis And Strategic Analysis Framework

6. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Segmentation

7. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Regional And Country Analysis

8. Asia-Pacific C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

9. China C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

10. India C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

11. Japan C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

12. Australia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

13. Indonesia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

14. South Korea C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

15. Western Europe C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

16. UK C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

17. Germany C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

18. France C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

19. Italy C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

20. Spain C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

21. Eastern Europe C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

22. Russia C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

23. North America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

24. USA C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

25. Canada C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

26. South America C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

27. Brazil C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

28. Middle East C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

29. Africa C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

30. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Competitive Landscape And Company Profiles

31. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Other Major And Innovative Companies

32. Global C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

34. Recent Developments In The C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market

35. C-X-C Chemokine Receptor 4 (CXCR4) Antagonists Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기